Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model

Kelly J. McKelvey1,2,3*, Amanda L. Hudson1,2,3, Ramyashree Prasanna Kumar1,2, James S. Wilmott4,5, Grace H. Attrill4,5, Georgina V. Long4,5,6,7, Richard A. Scolyer4,5,8, Stephen J. Clarke1,2,6, Helen R. Wheeler1,2,3,6, Connie I. Diakos1,2,6, Viive M. Howell1,2,3

1 Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, The University of Sydney Northern Clinical School and Northern Sydney Local Health District, St Leonards, NSW, Australia, 2 Sydney Vital Translational Research Centre, Royal North Shore Hospital, St Leonards, NSW, Australia, 3 The Brain Cancer Group, St Leonards, NSW, Australia, 4 Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia, 5 Charles Perkins Centre, The University of Sydney, Camperdown, NSW, Australia, 6 Northern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia, 7 Mater Hospital, North Sydney, NSW, Australia, 8 Royal Prince Alfred Hospital and New South Wales Health Pathology, Sydney, NSW, Australia

* kelly.mckelvey@sydney.edu.au

Abstract

Glioblastoma, the most aggressive form of glioma, has a 5-year survival rate of <5%. While radiation and immunotherapies are routinely studied in the murine Gl261 glioma model, little is known about its inherent immune response. This study quantifies the temporal and spatial localization of immune cell populations and mediators during glioma development. Eight-week old male C57Bl/6 mice were orthotopically inoculated with 1x10^6 Gl261 cells and tumor morphology, local and systemic immune cell populations, and plasma cytokines/chemokines assessed at day 0, 1, 3, 7, 14, and 21 post-inoculation by magnetic resonance imaging, chromogenic immunohistochemistry, multiplex immunofluorescent immunohistochemistry, flow cytometry and multiplex immunoassay respectively. From day 3 tumors were distinguishable with >30% Ki67 and increased tissue vascularization (p < 0.05). Increasing tumor proliferation/malignancy and vascularization were associated with significant temporal changes in immune cell populations and mediators during glioma development. Eight-week old male C57Bl/6 mice were orthotopically inoculated with 1x10^6 Gl261 cells and tumor morphology, local and systemic immune cell populations, and plasma cytokines/chemokines assessed at day 0, 1, 3, 7, 14, and 21 post-inoculation by magnetic resonance imaging, chromogenic immunohistochemistry, multiplex immunofluorescent immunohistochemistry, flow cytometry and multiplex immunoassay respectively. From day 3 tumors were distinguishable with >30% Ki67 and increased tissue vascularization (p < 0.05). Increasing tumor proliferation/malignancy and vascularization were associated with significant temporal changes in immune cell populations and mediators during glioma development. From day 3 tumors were distinguishable with >30% Ki67 and increased tissue vascularization (p < 0.05). Increasing tumor proliferation/malignancy and vascularization were associated with significant temporal changes in immune cell populations and mediators during glioma development. From day 3 tumors were distinguishable with >30% Ki67 and increased tissue vascularization (p < 0.05). Increasing tumor proliferation/malignancy and vascularization were associated with significant temporal changes in immune cell populations and mediators during glioma development.
can develop from the progression of lower grade gliomas [1]. In Australia, glioblastomas account for ~1,000 HGG cases per year and have a dismal prognosis of 12–16 months. While our understanding of the tumor biology has increased, patient outcomes have not improved significantly in the last 2 decades. At present the standard therapy for GBM remains maximum safe surgical resection, concomitant chemo-radiation, adjuvant chemotherapy, with/without the addition of anti-angiogenic drug bevacizumab (Avastin™) as a second line treatment.

While this multi-modal therapy has brought a modest overall survival benefit in patients with temozolomide (TMZ)-treatable methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter, it confers little benefit in the 50% of GBM patients with an unmethylated MGMT promoter [2]. Greater therapeutic options are desperately required.

Immunotherapies have been suggested as a potential therapy in the notoriously immunogenically ‘cold’ GBM tumors. Vaccines [3, 4], oncolytic viruses [5] and cannabis compounds (THC and CBD; clinical trial NCT01812603) are showing promise in Phase II/III clinical trials. Yet, while our understanding of brain cancer tumor biology has advanced, the modulation of the anti-tumor immune response with these therapeutic interventions as single-modal agents or in combination with standard care remains comparatively poorly understood. As we move toward personalized medicine, our ability to monitor and track an individual’s immune response to the developing glioma and response to different therapeutic intervention will become of paramount importance to determine what therapy should be administered and when in order to support tumor stabilization/elimination. This has precedence. The IMMOGLIO-01 glioma clinical trial published a case study of a 53-year old women with GBM in which longitudinal monitoring of her immune response during the treatment regimen, noted that a shift of the CD4:CD8 ratio was associated with magnetic resonance imaging (MRI) tumor progression [6].

Intra-tumoral heterogeneity is a hallmark of GBM [7], and recurrence is associated with polarization toward an immunosuppressive microenvironment [8]. Inflammation and coagulation play significant roles in tumor elimination, equilibrium and escape [9, 10] and by better understanding how standard therapy modulates this microenvironment [10, 11] we may better harness the immune system to treat these tumors. The use of animal models has transformed this area with the development of grafted syngeneic, immunocompromised and humanized patient-derived xenograft, and spontaneous genetically-modified or chemically-induced mouse models each with their own advantages and disadvantages [12–15]. For example, they have revealed that genetic driver mutations create unique microenvironments in GBM [16, 17] and have enabled longitudinal and multiregional investigation of novel effective therapeutics on the tumor [18], where repeat needle biopsies in this patient population is fraught with challenges. In the interest of assessing immunotherapies and targeted therapies in brain cancer such models offer a valuable preclinical resource [19].

The murine Gl261 glioma model has been well utilized for novel therapeutics as a surrogate for brain cancer yet remains poorly characterized from the tumor microenvironment and systemic immune response perspective. The current study builds upon the historical tumor biology reports in this model [20–24]. The overall aim of this study was to characterize the spatial and temporal immune response and tumor microenvironment in the murine Gl261 glioma model and determine whether plasma mediators correlate with tumor immunity. The findings confirm the dynamic processes of immune response during tumor development in both local and systemic compartments and show that at day 14 post-inoculation the decrease in plasma cytokines/chemokines correlates with an increase in cytotoxic T cells (Tc), natural killer (NK) and NK/T cells in the tumor infiltrate.
Materials and methods

Mice

Murine glioma Gl261 cells were kindly donated by Géza Sáfrány (Frederic Joliot-Curie National Research Institute for Radiobiology and Radiohygiene, Hungary) and cultured in Dulbecco’s Modified Eagles Medium containing 10% v/v fetal calf serum at 5% CO$_2$ and 95% humidified air atmosphere at 37˚C. The animal study was reviewed, approved and performed in accordance with the Northern Sydney Local Heath District Animal Ethics Committee guidelines, Royal North Shore Hospital, St Leonards, Australia (Approval #RESP/17/205) which enforces the New South Wales Animal Research Act 1985.

Eight-week old male C57Bl/6 mice (20–26 g) were provided by the Kearns’ Animal Facility, Australia. Mice were housed in Allentown individually ventilated cages (5 per cage) with cellulose bedding under Specific Pathogen Free conditions. Enrichment was provided in the form of autoclaved ice block sticks or straws. Rooms were temperature controlled (22˚C) and kept on 12-hour light/dark cycle (7:00/19:00 hr) with standard chow and water ad libitum.

Mice were inoculated with 1x10$^6$/2μl murine glioma Gl261 cells using a stereotactic frame, microinjection unit (David Kopf Instruments) and 5μl syringe with custom 32G needle (Hamilton Company) into the right caudoputamen (striatum) at mediolateral 2mm, anteroposterior -0.1mm, dorsoventral 2.6mm Bregma under isoflurane anesthesia (2% v/v per 1L oxygen i.h.). Mice were randomly assigned into one of six time point groups (15 mice per group) by weight to achieve an equal mean baseline weight per group (23.7 ± 0.15 g) in the treatment/tumor naïve animals. Animal weight and well-being was assessed twice weekly, and then at the predetermined endpoints of 0, 1, 3, 7, 14, and 21 days post-inoculation mice were euthanised by cardiac puncture under isoflurane anesthesia (2% v/v per 1L oxygen i.h.) followed by cervical dislocation. No adverse events were encountered. Ex vivo magnetic resonance imaging (MRI) was performed on 3 mice per time point, and histopathology, immune cell and cytokine analyses were performed on 12 mice per time point.

MRI

Brains were harvested and fixed in 10% v/v neutral buffered formalin (NBF) for 24 hr and washed in phosphate buffered saline (PBS). Ex vivo single non-contrast T2-weighted 2D RARE quick scans were acquired using a Biospec Avance III 94/21 USR preclinical MRI (Bruker BioSpin) performed by the Biological Resources Imaging Laboratory, University of New South Wales. Echo time = 45 ms; repetition time = 2559.348 s; number of averages = 16; matrix = 256 × 128; 23 slices; slice thickness = 500 μm.

Histopathology

Tumor morphology and necrosis was assessed by Mayer’s hematoxylin and eosin Y/erythrosin B staining.

Brains were harvested and fixed in 10% v/v NBF for 24 hr. Following paraffin embedding, 4μm sections were rehydrated and microwave antigen retrieval performed in citrate buffer, pH 6.0. Next, sections were blocked with 2.5% v/v normal goat serum and incubated with primary antibody for 1hr at room temperature; CD31 (0.013μg/ml; 77699) and Ki67 (0.0835μg/ml; 12202; Cell Signaling Technologies). For detection, sections were incubated with ImmPRESS™ horse radial peroxidase (HRP) goat anti-rabbit immunoglobulin G (IgG) polymer (MP-7451; Vector Labs) for 30min at room temperature and visualized using NovaRed (SK-48000; VectorLabs).

Stained slides were digitally scanned using the Aperio AT2 Digital Pathology Scanner. For histopathological assessment five random digital images of the tumor region per slide was
captured at 20x magnification using Aperio ImageScope (v12.3.2.8013; Leica Biosystems). Areas of normal brain tissue and tumor necrosis were excluded and then Ki67 positive staining was quantified by ImmunoRatio ImageJ plugin (v1.0c, 14.2.2011; http://jvsmicroscope.uta.fi/immunoratio/) and CD31 positive vessels enumerated and measured using the Microvessel-Segmentation MATLAB plugin [25].

**Multiplex fluorescent immunohistochemistry**

Sections were sequentially stained using the OPAL polymer anti-rabbit HRP (PerkinElmer) or ImmPRESS™ HRP goat anti-rat IgG polymer (MP-7404; Vector Labs) with the following primary antibodies for 1 hour at room temperature; Panel 1: CD3 (0.3μg/ml; A045201; DAKO), CD4 (0.31μg/ml; ab183685; Abcam), CD8 (0.50μg/ml; ab203035; Abcam), FoxP3 (0.05μg/ml; 12653S; Cell Signaling Technologies), CD161 (0.031μg/ml; ab234107; Abcam), and Ki67 (0.084μg/ml; 12202S; Cell Signaling Technologies); Panel 2: ARG1 (0.125μg/ml; ab91279; Abcam), iNOS (8μg/ml; ab3523; Abcam), F4/80 (0.22μg/ml; 70076S; Abcam), TMEM119 (0.076μg/ml; ab209064; Abcam), CD19 (0.02μg/ml; 90176S; Cell Signaling Technologies), and Ki67 (0.084μg/ml; 12202S; Cell Signaling Technologies); Panel 3: Ly6C (0.10μg/ml; ab15627), Ly6G (0.25μg/ml; ab25377; Abcam), CD11b (0.085μg/ml; ab133357; Abcam), F4/80 (0.22μg/ml; 70076S; Cell Signaling Technologies), GFAP (1.45μg/ml; Z033401-2; DAKO) and Ki67 (0.084μg/ml; 12202S; Cell Signaling Technologies). Six color OPAL reagents were utilized (1:100 OPAL 520, 540, 570, 620, 650, 690) and all sections counterstained with DAPI for nuclei. Sections were scanned at 10x, regions of interest denoted in Phenochart version 1.0.2, and then multi-spectral images (MSI) acquired at 20x using a VECTRA 3.0 Automated Quantitative Pathology Imaging System (PerkinElmer). Spectral unmixing and cell phenotypes were quantified using inForm version 2.4 software (PerkinElmer) with technical assistance from the Sydney Microscopy and Microanalysis Unit, University of Sydney.

Immune cell populations were defined as CD3⁺ T cell, CD3⁺CD4⁺ helper T-lymphocytes (Th), CD4⁺FOXP3⁺ regulatory T cells (Treg), CD3⁺CD8⁺ Tc, CD161⁺ NK cells, CD3⁺CD161⁺ NK/T, F4/80⁺ macrophage (Mac), F4/80⁺iNOS⁺ type I macrophage (M1), F4/80⁺ARG1⁺ M2, TMEM119⁺/iNOS⁺ type I microglia (M1 microglia), TMEM119⁺/ARG1⁺ type II microglia (M2 microglia), CD11b⁺ dendritic cell (DC), CD11b⁺Ly6Chigh monocytemyeloid derived suppressor cells (M-MDSC), CD11b⁺Ly6Chigh polymorphonuclear (PMN)-MDSC, and CD19⁺ B cells expressed as mean number of cells per high power field (HPF).

**Hematology and flow cytometry**

Whole blood (1ml) was collected via cardiac puncture into K3EDTA tubes (Minicollect®; Greiner Bio-One) and red blood cell, lymphocyte and platelet counts acquired by COULTER Ac-T diff hematology analyzer with the Vet App 1.06 (Beckman Coulter).

To assess systemic immune cell populations multi-color flow cytometry was employed. Using 100μl whole blood, 1x10⁶ splenocytes and 1x10⁶ bone marrow-derived cells, red blood cell were lysed and leukocytes stained with a cocktail of antibodies; CD25-BV421 (1μl; 564370), FVS10-BV510 (1μl; 564006), CD80-BV605 (1μl; 563052), NK1.1-BV650 (1μl; 564143), CD64-BV711 (0.25μl; 563726), CD117-BV786 (1μl; 564012), CD11b-BB515 (0.25μl; 564454), CD19-PerCP/Cy5.5 (1μl; 551001), CD115-PE (0.25μl; 565249), Ly6G-PE/CF594 (0.06μl; 562700), CD3-PE/Cy7 (1μl; 552774), CD206-AF647 (1μl; 565250), CD8α-AF700 (0.25μl; 557959), Ly6C-APC/Cy7 (0.5μl; 560596; all BD Biosciences). Data was acquired using a BD LSRRFortessa™ and analyzed using BD FACSDiva™ Software version 6 (BD Biosciences).

Immune cell populations were defined as CD3⁺ T cell, CD3⁺CD4⁺ Th, CD3⁺CD4⁺ CD25⁺ Treg, CD3⁺CD8 Tc, CD3⁺NK1.1⁺ NK, CD3⁺NK1.1⁺ NK/T, CD115⁺CD11b⁺ monocytes,
CD115⁺CD11b⁺CD80⁺ M1, CD115⁺CD11b⁺CD206⁺ M2, CD115⁻CD11b⁻ DC, CD115⁻CD11b⁻Ly6C⁺Ly6G⁻ M-MDSC, CD115⁻CD11b⁺Ly6C⁻Ly6G⁺ PMN-MDSC, CD117⁺ hematopoietic stem cell (HSC), CD19⁺ B cells and expressed as a percentage of the parent population.

**Multiplex immunoassays**

Plasma was obtained from whole blood by centrifugation at 500 x g for 5 minutes at room temperature. Mouse cytokine 23-plex immunoassay (Bio-Plex; Bio-Rad Laboratories) and chromogenic sandwich enzyme-linked immunosorbent assay (ELISA) for TGF-β1 (DY1679; R&D Systems) were performed in accordance with the manufacturer’s instructions.

**Statistical analyses**

Histological data are expressed as the mean of five HPF ± standard error of the mean (SEM) and assessed for significance using One Way Analysis of Variance (ANOVA) with Tukey’s Multiple Comparison Test. Hematology, flow cytometry and chemokine/cytokine data are expressed as median ± interquartile range due to significant differences in standard deviation for some parameters, as determined by the Brown-Forsythe Test for normality. Kruskal-Wallis One Way ANOVA with Dunn’s Multiple Comparison Test was performed using Prism 7 for Windows (GraphPad Software, Inc). Multiplex immunofluorescent data are expressed as the mean of all 20x HPF MSI covering the tumor region (or equivalent brain region in D0 sham controls) ± SEM. Statistical significance was assessed by One Way ANOVA with Tukey’s Multiple Comparison Test. Relationships between plasma cytokine levels and tumor infiltrate were assessed by Pearson correlation. All statistical analyses were performed using Prism 7 for Windows (GraphPad Software, Inc) and statistical significance deemed p-value less than 0.05.

LOESS curves (local polynomial regression) were generated and plotted using the ggplot2 package in R and RStudio [26, 27] to model the dynamic changes in the tumor and systemic immune response during GL261 glioma development.

**Results**

**MRI demonstrated visible tumor growth from day 14 with mass effect and contralateral edema**

While the needle tract was evident at the early time points, definitive tumor morphology was only distinguishable on the non-contrast T2-weight scans from day 14 post-inoculation (Fig 1). Tumors grew posteriorly into the hippocampal and mid brain regions and were associated with mass effect and a midline shift at day 14 (Fig 1). Marked brain edema in the contralateral hemispheres of brains from the day 21 cohort was also observed. Dark (hematoma) and brighter intensity (fluid-filled) regions were also observed in the central region of the tumors at day 21 post-inoculation.

**Tumors showed increasing proliferative rates, blood vasculature and geographic necrosis**

Hematoxylin and eosin-based tissue morphology demonstrated the progressive infiltration and development of the glialoma within the caudoputamen region (Fig 2A). Sham-operated (D0) brains showed a region of hemorrhage at the margin of the needle tract, which largely resolved by day 1–3. At day 3 the cells show uniform shape and nuclei, which progressed to an elongated, morphology at days 7 and 14. At day 21 the cells are densely packed and show heterogeneous cellular size and nuclear formations (Fig 2B).
Quantification of Ki67 staining showed increasing cell proliferation within the tumor microenvironment up to day 14 (Fig 3A). As the tumors enlarged beyond day 14, centralized regions showed evidence of necrosis. At day 21, where centralized foci of geographic necrosis were present, Ki67 positivity of the surrounding tumor tissue decreased (Fig 3B). Cell proliferation peaked from day 3–14 post-inoculation (mean ± SEM; D3 32.99 ± 3.68%; D7 37.78 ± 3.74%; D14 37.95 ± 2.09%) compared to sham-operated (D0 4.58 ± 0.50%; Fig 3C). At day 21 there was regional heterogeneity in Ki67 with higher levels at the peripheral/leading edge of the tumor and lower levels in the intermediate zone and avascular tumor center and regions of geographic necrosis (S1 Fig).

To confirm that blood vasculature within the tumor contributed to the necrotic regions, the number and size (lumen area) of CD31+ blood vessels was quantified within the tumor microenvironment (Fig 4A). The number of vessels peaked at day 3 (26.38 ± 1.45) in the immediate tumor periphery indicating a pro-angiogenic wound healing response to the needle-based inoculation of cells. At day 7 (17.11 ± 3.05) and 14 (13.77 ± 1.99; Fig 4B) vessel numbers increased compared to D0 and were homogeneous and small (lumen area ~0.02 μm²). At day 21 a significant increase in the number of blood vessels and mean lumen area was present as blood vessels were larger (lumen area 0.04μm²; Fig 4C). Other vasculature parameters assessed were vessel thickness, perimeter and area—but were not significantly different between time points.

**M2 macrophages and MDSCs are more prominent than Tregs in the tumor immune infiltrate**

Three multiplex antibody panels were used to assess the infiltration of lymphocytes (Panel 1), macrophages (Panel 2) and DC (Panel 3) populations into the brain tumors using multiplex
fluorescent immunohistochemistry (Fig 5A). An example of the single-color panels and dynamic change in immune cell populations of the macrophage panel are provided in Supplementary S2 Fig and S3 Fig, respectively. Quantitative assessment showed that T and B cell populations increased significantly over time, with Tregs peaking at day 7 (mean ± SEM; 0.20 ± 0.00 cells per HPF) compared to days 0 and 21 where Tregs were absent (both 0.00 ± 0.00 cells per HPF; p < 0.05; Fig 5B). CD4⁺ Th, CD8⁺ Tc, NK and NK/T cells showed no significant differences over time. Mac, M2, microglia and M2 microglia increased over time peaking at day 14, while M1 spiked at days 7 (2.72 ± 0.02 cells per HPF; p < 0.0001) and 21 (4.20 ± 0.01 cells per HPF; p < 0.0001) compared to day 0 (0.06 ± 0.00 cells per HPF). Among the DC populations, DC, M-MDSC and PMN-MDSC populations significantly increased from day 3 and spiked at day 21 (DC 18.62 ± 0.07, M-MDSC 7.88 ± 0.03, PMN-MDSC 11.44 ± 0.04 cells per HPF; all p < 0.0001; Fig 5B). Anti-tumor/immunosuppressive populations were dynamic and did not all appear/disappear at the same time or to similar levels (Fig 5C); Tregs peaked at day 7 but remained at markedly lower levels than M2 macrophages and MDSCs which peaked at day 14 and day 21 respectively (Fig 5C).
Systemic immunity to glioma development is dynamic but does not directly correlate with the tumor infiltrate

To assess the systemic immune response, hematological parameters and immune cell populations in the spleen, bone marrow and peripheral blood were quantified by flow cytometric analysis. In response to the tumor inoculation wound, platelets decreased by 20% at day 1 compared to day 0 ($p < 0.005$) but normalized by day 3 (Panel A in Supplementary S4 Fig). Total circulating white blood cells were increased at day 14 (Fig 6) and further delineated for temporal modulation of the immune cell populations in peripheral blood, as well as the spleen and bone marrow compartments. The gating strategy for delineation of the immune cell populations is shown in Panel B in Supplementary S4 Fig.

Within the spleen, Tregs and PMN-MDSC significantly decreased by ~10% and ~40%, respectively, at day 14 post-inoculation, while Tc, M2 and M-MDSCs all peaked at day 14 when compared to other time points assessed (Fig 6).

In patients with glioma, immune cell populations are reported to sequester in the bone marrow compartment [28]. Consistent with this notion, the data here show that in bone marrow,.....
‘anti-tumor’ populations T cell, Th, NK, NK/T, M1 and B cells all decreased at day 3 and were highest at day 21 (Fig 6) potentially suggesting progressive sequestration within the bone marrow compartment, though local expansion of these immune cell populations is also plausible. In the immunosuppressive populations, Tregs decreased at day 21 compared to day 0, meanwhile the MDSC populations showed an inverse relationship to one another; M-MDSCs were lowest at day 7 and peaked at day 1 and 21, yet PMN-MDSCs peaked at day 7, and were lowest at day 1 and 21 (Fig 6B).

In peripheral blood, Th and Treg populations decreased 12% and 30% at day 21 compared to day 0, respectively (Fig 6B). NK/T peaked at day 14 and Tcs at day 21. The significant increase in monocytes at day 14, was reciprocated with a decline in M1 cells and absence of M2 suggesting migration from peripheral blood into the tumor/parenchyma (Fig 6B). Correlation of the systemic peripheral blood immune cell populations quantified by flow cytometry, and immune cell infiltrate assessed by multiplex fluorescent immunohistochemical staining showed no significant correlations, except for M1 macrophages which showed a moderate correlation ($r^2 = 0.3849$, $p = 0.0003$; Pearson’s correlation). This suggests that non-invasive

---

Fig 4. Number of blood vessels in Gl261 gliomas. CD31+ blood vessels at the inoculation site of murine Gl261 gliomas (A). Scale bar, 200μm. Quantitation of blood vessels (B) and lumen area (C) in five HPF (20x) for each murine brain (N = 12 brains per time point; B). Data are expressed as mean ± SEM per HPF. (B) $^a$p<0.05 vs D0, $^b$p<0.05 vs D1, $^c$p<0.05 vs D3, $^d$p<0.05 vs D14 by Tukey’s multiple comparison test. (C) $^a$p<0.05 vs 21 by Tukey’s multiple comparison test. https://doi.org/10.1371/journal.pone.0226444.g004

---

https://doi.org/10.1371/journal.pone.0226444.g004
Fig 5. Tumor immune cell infiltrate. (A) Whole slide scans (4x) and MSI spectrally unmixed and pseudo-colored micrographs (20x) of the three immune cell panels for lymphocytes, macrophages and DC populations in the tumor infiltrate. (B-C) Quantitation of immune cell phenotypes in HPF for each murine brain (N = 6 brains per time point). Data are expressed as mean ± SEM per HPF (B) and as mean percentage normalized to day 0 (C). *p<0.05 vs D0, †p<0.05 vs D1, ‡p<0.05 vs D3, §p<0.05 vs D7, ¶p<0.05 vs all other time points by One-way ANOVA with Tukey’s multiple comparison test.

https://doi.org/10.1371/journal.pone.0226444.g005
assessment of peripheral blood immune cell populations does not reflect the tumor infiltrate in this model.

Plasma cytokines, chemokines and growth factors correlate with an increase in Tc, NK and NK/T cells at day 14

To determine whether the change in immune cell response is indicated by a change in plasma cytokine levels, a panel of 24 cytokines was assessed by multiplex immunoassay or ELISA. The
results are shown in Fig 7. At day 1, G-CSF increased 4.5-fold compared to day 0 consistent with a role in neutrophil mobilization and an early wound healing response. The pleiotropic cytokine, IL-6 was also increased ~3-fold at day 1 compared to sham-operated animals (day 0). At day 14, 16 of the 24 cytokines, chemokines and growth factors assessed were significantly decreased; IL-1β, IL-3, IL-4, IL-6, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IFN-γ, TNF-α, G-CSF, GM-CSF, CCL2 and CCL3 (Fig 7).

Correlation studies of the plasma cytokines levels and tumor infiltrates for each animal revealed that as the above cytokines decreased at day 14, there was an increase in Tc, NK and NK/T cells in the tumor ($r^2 = 0.92$ to 0.99; $p = 0.001$ to 0.04; Fig 8A). In contrast, CCL11 and TGF-β levels increased with an increase in these immune cell types in the immune infiltrate ($r^2 = 0.095$ to 0.99; $p = 0.001$ to 0.03), as well as in NK and monocyte populations in the bone.
marrow (Fig 8B). Plasma IL-6 and G-CSF positively correlated with splenic DC and PMN-MDSC at all time points, M-MDSC were negatively correlated, consistent with roles in MDSC phenotypic development (Fig 8B). To model the dynamic changes in tumor infiltrate, systemic immune response and plasma cytokines and chemokines during glioma development LOESS curves were fitted (local polynomial regression) and plotted using the ggplot2 package in R [26, 27] (S5 Fig).

Discussion

In this study we provide a comprehensive characterization of the immune response in the murine syngeneic Gl261 glioma model both temporally and spatially. This is the most widely used mouse model for GBM and with the increasing interest in immunotherapeutics, ‘point of reference’ knowledge of the inherent immune response within this model is central to the interpreting efficacy studies. Tracking the immune response to glioma and subsequent treatment therapies will additionally aid the design of optimal treatment strategies.

Histopathologically the murine Gl261 tumors are poorly differentiated similar to human GBM cells [20, 21] with individual cell infiltration and invasion millimeters from the tumor...
boundary into normal brain tissue [23, 24]. Consistent with other reports of Gl261 tumor morphology, from day 3 Gl261 cells showed uniform size and shape which progressed to elongated cells at day 7–14 with perivascular satellitosis, and increasing microvascular density and Ki67 proliferation indices [29, 30]. At day 21 cells and nuclei showed heterogenic size and shape and the presence of centralized necrosis [23, 24, 29]. Within the mature (day 21) tumors intratumoral heterogeneity of the Ki67 staining, and blood vessel number and lumen size was present when compared to D7 to D14 tumors. This has precedence. Investigations of the tumor blood vasculature using microscopic techniques show that established orthotopic rodent tumors (4-10mm diameter) develop defined vascular regions; (i) avascular and occasionally necrotic centre, (ii) intermediate zone of pleomorphic blood vessels of 3–40μm diameter, and (iii) a peripheral region of uniform immature blood vessels of <5μm diameter [31]. As a result, the higher mean Ki67 at D7 and 14, compared to D21, is potentially supported by the increased diffusion from numerous, but immature/leaky blood vessels of the smaller tumor. Meanwhile, the lower mean Ki67 in D21 despite increased number and lumen area of blood vessels is due to the presence of abnormal/dysmorphic vasculature common in gliomas and replicated in the Gl261 model [31–33]; expanded vessels, increased leakage, and loss of branching complexity [33] leading to reduced Ki67 proliferation and regions of geographic necrosis.

At day 3 a spike in the number of blood vessels likely associated with pro-angiogenesis from the needle-induced wound tract was observed. From most brain cancer patients, maximal safe surgical resection to alleviate symptoms is a crucial first step in the treatment regime. Surgery typically precedes chemoradiation by up to four weeks and may affect clinical outcome (overall and progression free survival), though clinical trial data is discrepant [34]. The role of inflammation from wound healing processes on glioma development (or recurrence) is poorly investigated in preclinical models. As such there is a paucity of data on how a pre-activated immune response due to wound healing, and hypoxia and edema in the remaining tumor bed alter the subsequent immune response to therapeutic agents and the therapeutic efficacy on GBM. As this may contribute to the failure of drugs from preclinical studies to clinical trials further studies in this area are required.

Despite Gl261 tumors being noted as partially immunogenic, expressing MHC I but low levels of MHC II, B7-1 and B7-2 [35], we saw no significant differences in ‘anti-tumor’ Th, Tc, NK and NK/T immune cell populations infiltrating the tumor microenvironment over time, although a correlation with decreasing plasma cytokines was noted at day 14 post-inoculation. TMEM119 was used to identify resident microglia from infiltrating macrophages in murine and human central nervous system tissue [36, 37], and showed little variation over time indicating that the resident population does not expand, but infiltrating macrophages contribute to the immune response. Among the ‘immunosuppressive’ populations, M-MDSC and PMN-MDSC significantly increased at day 3, then declined; Tregs spiked at day 7, and M2 at day 14. Finally, M-MDSC and PMN-MDSC spiked at day 21 when Tregs were absent. As aforementioned the marked decrease in 16 of 24 plasma cytokines and chemokines at day 14 correlated with an increase in pro-tumor cell types Tc, NK and NK/T cells, potentially indicating a re-activation of the immune response at this time point. We tentatively speculate that this may be associated with tumor immune escape [38].

The inter-relationship of Tregs, DCs and macrophages in glioma is complex. An absence of Tregs causes a phenotypic shift in macrophage populations toward M1 [39], while macrophages and microglia produce CCL2 within the glioma microenvironment, a chemokine that is critical for the recruitment of Treg and M-MDSCs [40]. Gl261 tumors grown in CCL2-deficient mice or mice treated with a small-molecule antagonist of CCL-2 receptor, CCR4, failed to maximally accumulate Tregs and M-MDSCs within the glioma microenvironment [40]. In our study plasma CCL2 levels peaked on day 7 and were markedly reduced at day 14 post-
inoculation coinciding with changes in MDSCs within the tumor microenvironment, but not Tregs. Recent studies have shown bidirectional regulation of Treg cells and MDSCs directly through TGF-β\([41]\), programmed cell death-1 (PD-1) and its ligand PD-L1\([42]\), and indirectly by controlling differentiation of Treg and regulatory DCs\([43]\). Plasma TGF-β1 increased day 14 and 21 though was not significantly different due to heterogeneous levels but correlated with tumor microglia across all times points.

In line with the upsurge in immunotherapy success in certain cancers, those which target T cell populations have become the focus of preclinical Gl261 studies of late. Checkpoint inhibitors PD-1, PDL-1 and TIM3 which regulate self-tolerance and Th1 responses respectively, and the rate-limiting metabolic enzyme and Treg modulator indoleamine 2,3-dioxygenase doubled median survival and increased long-term survival in cohorts when combined with acute radiation\([44–46]\). The effect required continuous CD4\(^{+}\) T cell involvement\([46]\). Interestingly the inclusion of TMZ chemotherapy with the trimodal anti-PD1, anti-TIM3 and radiation therapy reduced the number of long-term survival animals by 90%\([46]\). The effect of TMZ on T cell populations is described elsewhere\([47]\), though more data is needed in regards to combination therapy with novel immunotherapeutics.

**Conclusion**

The current study shows that there are dynamic immunomodulatory effects in the local and systemic compartments during glioma development and warrants comprehensive tracking during the preclinical assessment of novel therapeutics. Early data from the IMMO-GLIO-01 glioma clinical trial which tracks the immune response during treatment regimens demonstrates the value of such information. In a case study, RT treatment coincided with declines in T cells, B cells, pDCs and NK cells, and a shift of the CD4:CD8 ratio correlated with MRI tumor recurrence offering some hope in the identification of treatment response or prognostic indicators\([6]\). In the move toward personalized medicine, tracking of the patient immune response before, during and after treatment and with different treatment combinations will give greater understanding of when and what therapy should be administered at each time point to induce/maintain a state of tumor stabilization/elimination. The current preclinical study aids this notion by providing critical insight into the dynamic immune response to glioma, the immunosuppressive immune cells that predominate the tumor infiltrate (M2, M2 microglia and MDSC vs Treg), and that changes in plasma cytokine profiles may indicate changes in the tumor immune infiltrate. Further exploration of the dynamic immune response in the context of novel therapeutics for glioblastoma is warranted in this model.

**Supporting information**

**S1 Checklist.** Arrive guidelines checklist.

(DOCX)

**S1 Fig.** Ki67 and CD31 staining shows heterogeneity among different tumor regions.

(TIF)

**S2 Fig.** Single color panels of the multiplex immunofluorescent IHC.

(TIF)

**S3 Fig.** Dynamic response of the immune infiltrate in glioma.

(TIF)

**S4 Fig.** Hematological parameters and flow cytometry gating strategy.

(TIF)
S5 Fig. Dynamics of the tumour and systemic immune response modelled using LOESS curves.

(TIF)

Acknowledgments

We thank the following units for technical assistance; Biological Resources Imaging Laboratory, University of New South Wales (MRI); Histology Services, Hunter Medical Research Institute (histopathology); and Sydney Microscopy and Microanalysis Unit, The University of Sydney (multiplex fluorescent immunohistochemistry).

Author Contributions

Conceptualization: Kelly J. McKelvey, Amanda L. Hudson, Stephen J. Clarke, Helen R. Wheeler, Connie I. Diakos, Viive M. Howell.

Formal analysis: Kelly J. McKelvey.

Funding acquisition: Connie I. Diakos, Viive M. Howell.

Investigation: Kelly J. McKelvey, Amanda L. Hudson, Ramyashree Prasanna Kumar.

Methodology: Kelly J. McKelvey, James S. Wilmott, Grace H. Attrill.

Project administration: Kelly J. McKelvey.

Resources: James S. Wilmott, Grace H. Attrill, Georgina V. Long, Richard A. Scolyer.

Supervision: Stephen J. Clarke, Helen R. Wheeler, Connie I. Diakos, Viive M. Howell.

Visualization: Kelly J. McKelvey.

Writing – original draft: Kelly J. McKelvey.

Writing – review & editing: Kelly J. McKelvey, Amanda L. Hudson, Ramyashree Prasanna Kumar, James S. Wilmott, Grace H. Attrill, Georgina V. Long, Richard A. Scolyer, Stephen J. Clarke, Helen R. Wheeler, Connie I. Diakos, Viive M. Howell.

References

1. Brain and other central nervous system cancers. In: 2017 AIoHaW, editor. Canberra: AIHW; 2017.

2. Wick W, Weller M, van den Bent M, Sason M, Weiler M, von Deimling A, et al. MGMT testing—the challenges for biomarker-based glioma treatment. Nature Reviews Neurology. 2014; 10(7):372–85. https://doi.org/10.1038/nrneurol.2014.100 PMID: 24912512

3. Liau LM, Ashkan K, Tran DD, Campion JL, Trusheim JE, Cobbs CS, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. Journal of translational medicine. 2018; 16(1):142. Epub 2018/05/31. https://doi.org/10.1186/s12967-018-1507-6 PMID: 29843811.

4. Cuoco JA, Benko MJ, Busch CM, Rogers CM, Prickett JT, Marvin EA. Vaccine-based immunotherapeutics for the treatment of glioblastoma: Advances, challenges, and future perspectives. World Neurosurgery. 2018; 120:302–15. https://doi.org/10.1016/j.wneu.2018.08.202 PMID: 30196171

5. Martikainen M, Essand M. Virus-based immunotherapy of glioblastoma. Cancers. 2019; 11(2):186. https://doi.org/10.3390/cancers11020186 PMID: 30764570.

6. Ruhle PF, Goerig N, Wunderlich R, Fietkau R, Gaipil US, Strnad A, et al. Modulations in the peripheral immune system of glioblastoma patient is connected to therapy and tumor progression-A case report from the IMMO-GLIO-01 Trial. Frontiers in neurology. 2017; 8:296. Epub 2017/07/12. https://doi.org/10.3389/fneur.2017.00296 PMID: 28969086; PubMed Central PMCID: PMC5481307.

7. Parker NR, Hudson AL, Khong P, Parkinson JF, Dwight T, Ikin PJ, et al. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Scientific Reports. 2016;
6:22477. https://doi.org/10.1038/srep22477https://www.nature.com/articles/srep22477#supplementary-information. PMID: 26940435

8. Hudson AL, Parker NR, Khong P, Parkinson JF, Dwight T, Ikin RJ, et al. Glioblastoma recurrence correlates with increased APE1 and polarization toward an immune-suppressive microenvironment. Frontiers in oncology. 2018; 8:314. https://doi.org/10.3389/fonc.2018.00314 PMID: 30153535.

9. Cho A, McKelvey KJ, Lee A, Hudson AL. The intertwined fates of inflammation and coagulation in glioma. Mammalian genome: official journal of the International Mammalian Genome Society. 2018; 29(11–12):806–16. Epub 2018/08/01. https://doi.org/10.1007/s00335-018-9761-8 PMID: 30062485.

10. Brown NF, Carter TJ, Ottaviani D, Mulholland P. Harnessing the immune system in glioblastoma. British Journal of Cancer. 2018; 119(10):1171–81. https://doi.org/10.1038/s41416-018-0258-8 PMID: 30393372

11. McKelvey KJ, Hudson AL, Back M, Eade T, Diakos CI. Radiation, inflammation and the immune response in cancer. Mammalian genome: official journal of the International Mammalian Genome Society. 2018; 29(11–12):843–65. https://doi.org/10.1007/s00335-018-9777-0 PMID: 30178305.

12. Chen L, Zhang Y, Yang J, Hagan JP, Li M. Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies. Biochimica et biophysica acta. 2013; 1836(1):158–65. Epub 04/22. https://doi.org/10.1016/j.bbcan.2013.04.003 PMID: 23618720.

13. Huszthy PC, Daphu I, Niclou SP, Stieber D, Nikrogh JM, Sakarissem PØ, et al. In vivo models of primary brain tumors: pitfalls and perspectives. Neuro-oncology. 2012; 14(8):979–93. Epub 06/07. https://doi.org/10.1093/neuonc/nos135 PMID: 22679124.

14. Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12(18):5288–97. Epub 2006/09/27. https://doi.org/10.1158/1078-0432.ccr-06-0438 PMID: 17000661.

15. Simeonova I, Huillard E. In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies. Cellular and molecular life sciences: CMLS. 2014; 71(20):4007–26. Epub 07/10. https://doi.org/10.1007/s00018-014-1675-3 PMID: 25030845.

16. Chen Z, Hambardzumyan D. Immune Microenvironment in Glioblastoma Subtypes. Frontiers in immunology. 2018; 9:1004–. https://doi.org/10.3389/fimmu.2018.01004 PMID: 29867979.

17. Herting CJ, Chen Z, Pitter KL, Szuilewsky F, Kaffes I, Kaluzova M, et al. Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas. Glia. 2017; 65(12):1914–26. Epub 08/24. https://doi.org/10.1002/glia.23203 PMID: 28836293.

18. Galibán S, Al-Holou WN, Wang H, Welton AR, Heist K, Hu XK, et al. MRI-Guided Stereotactic Biopsy of Murine GBM for Spatio temporal Molecular Genomic Assessment. Tomography. 2017; 3(1):9–15. https://doi.org/10.18383/j.tom.2017.00112 PMID: 28553660.

19. Chandramohan V, Sanchez-Perez L, He Y, Pirozzi CJ, Congdon KL, Bigner DD. Chapter 6—Preclinical Immunotherapeutic Animal Models for Brain Tumors. In: Sampson JH, editor. Translational Immunotherapy of Brain Tumors. San Diego: Academic Press; 2017. p. 111–47.

20. Shapiro WR, Ausman JI, Rall DP. Studies on the chemotherapeutic of experimental brain tumors: evaluation of 1,3-bis(2-chloroethyl)-l-nitrosourea, cyclophosphamide, mithramycin, and methotrexate. Cancer research. 1970; 30(9):2401–13. Epub 1970/09/01. PMID: 5475484.

21. Zagzag D, Aminovin R, Greco MA, Yee H, Holash J, Wiegrad SJ, et al. Vascular apoptosis and involvement in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Laboratory investigation; a journal of technical methods and pathology. 2000; 80(6):837–49. Epub 2000/07/01. PMID: 10879735.

22. Zagzag D, Esency M, Mendez O, Yee H, Sminovia I, Huang Y, et al. Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer’s structures. Am J Pathol. 2008; 173(2):545–60. Epub 2008/07/05. https://doi.org/10.1038/ajpath.2007.3870086 PMID: 18059607; PubMed Central PMCID: PMC2475791.

23. Newcomb EW, Zagzag D. The Murine GL261 Glioma Experimental Model to Assess Novel Brain Tumor Treatments. In: Meir EG, editor. CNS Cancer: Models, Markers, Prognostic Factors, Targets, and Therapeutic Approaches. Totowa, NJ: Humana Press; 2009. p. 227–41.

24. Zagzag D, Miller DC, Chiriboga L, Yee H, Newcomb EW. Green fluorescent protein immunohistochemistry as a novel experimental tool for the detection of glioma cell invasion in vivo. Brain pathology (Zurich, Switzerland). 2003; 13(1):34–7. Epub 2003/02/13. https://doi.org/10.1111/j.1750-3639.2003.tb00004.x PMID: 12880545.

25. Reyes-Aldasoro CC, Williams LJ, Akerman S, Kanthou C, Tozer GM. An automatic algorithm for the segmentation and morphological analysis of microvessels in immunostained histological tumor sections. Journal of Microscopy. 2011; 242(3):262–78. https://doi.org/10.1111/j.1365-2818.2010.0464.x PMID: 21118252.
26. Team RC. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017.

27. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York: Springer-Verlag New York; 2009.

28. Chongsaithidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nature Medicine. 2018; 24(9):1459–68. https://doi.org/10.1038/s41591-018-0135-2 PMID: 30104766

29. Kucheryavyykh LY, Kucheryavyykh YY, Rolón-Reyes K, Sketchkov SN, Eaton MJ, Cubano LA, et al. Visualization of implanted GL261 glioma cells in living mouse brain slices using fluorescent 4-(4-(dimethylamino)-styryl)-N-methylpyridinium iodide (ASP+). BioTechniques. 2012; 53(5):305–9. https://doi.org/10.2144/000113940 PMID: 23570046.

30. Burger PC SB, Vogel FS. Surgical Pathology of the Nervous System and its Coverings. New York: Churchill Livingstone; 2002.

31. Deane BR, Lantos PL. The vasculature of experimental brain tumours. Part 1. A sequential light and electron microscope study of angiogenesis. Journal of the neurological sciences. 1981; 49(1):55–66. Epub 1981/01/01. https://doi.org/10.1016/0022-510x(81)90188-x PMID: 7205320.

32. Doblas S, He T, Saunders D, Pearson J, Hoyle J, Smith N, et al. Glioma morphology and tumor-induced vascular alterations revealed in seven rodent glioma models by in vivo magnetic resonance imaging and angiography. Journal of magnetic resonance imaging: JMRI. 2010; 32(2):267–75. Epub 2010/08/03. https://doi.org/10.1002/jmri.22263 PMID: 20677250; PubMed Central PMCID: PMC2915452.

33. Mathivet T, Boulet C, Van Woensel M, Stanchi F, Verschueren T, Phng LK, et al. Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth. EMBO molecular medicine. 2017; 9(12):1629–45. Epub 2017/10/19. https://doi.org/10.15252/emmm.201607445 PMID: 29038312; PubMed Central PMCID: PMC5709745.

34. Han SJ, Englert DJ, Birk H, Molinaro AM, Chang SM, Clarke JL, et al. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015; 62 Suppl 1:160–5. Epub 2015/07/17. https://doi.org/10.1227/neu.0000000000000813 PMID: 26191937; PubMed Central PMCID: PMC5260825.

35. Satoh J, Kino Y, Asahina N, Takitani M, Miyoshi J, Ishida T, et al. Characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer science. 2006; 97(6):546–53. Epub 2006/06/01. https://doi.org/10.1111/j.1349-7006.2006.00208.x PMID: 16734735.

36. Satoh J, Kino Y, Asahina N, Takitani M, Miyoshi J, Ishida T, et al. TMEM119 marks a subset of microglia in the human brain. Neuropathology: official journal of the Japanese Society of Neuropathology. 2016; 36(1):39–49. Epub 2015/08/08. https://doi.org/10.1111/neup.12235 PMID: 26250788.

37. Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB, et al. New tools for studying microglia in the mouse and human CNS. Proceedings of the National Academy of Sciences. 2016; 113(12):E1738. https://doi.org/10.1073/pnas.1525528113 PMID: 26884166.

38. Bhatia A, Kumar Y. Cancer-immune equilibrium: questions unanswered. Cancer microenvironment: official journal of the International Cancer Microenvironment Society. 2011; 4(2):209–17. https://doi.org/10.1007/s12307-011-0065-8 PMID: 21607751.

39. Skuljec J, Jirmo AC, Habener A, Talbot SR, Pul R, Grychtol R, et al. Absence of Regulatory T Cells Causes Phenotypic and Functional Switch in Murine Peritoneal Macrophages. Frontiers in Immunology. 2018; 9(2458). https://doi.org/10.3389/fimmu.2018.02458 PMID: 30429849

40. Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, et al. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. Cancer research. 2016; 76(19):5671–82. Epub 2016/08/18. https://doi.org/10.1158/0008-5472.CAN-16-0414 PMID: 27530322; PubMed Central PMCID: PMC5050119.

41. Lee CR, Kwak Y, Yang T, Han JH, Park SH, Ye MB, et al. Myeloid-Derived Suppressor Cells Are Controlled by Regulatory T Cells via TGF-beta during Murine Colitis. Cell reports. 2016; 17(12):3219–32. Epub 2016/12/24. https://doi.org/10.1016/j.celrep.2016.11.062 PMID: 28099291.

42. Zhang Y, Velez-Delgado A, Mathew E, Li D, Mendez FM, Flannagan K, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut. 2017; 66(1):124–36. Epub 07/08. https://doi.org/10.1136/gutjnl-2016-312078 PMID: 27402485.

43. Shurin GV, Ma Y, Shurin MR. Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer microenvironment: official journal of the International Cancer Microenvironment Society. 2013; 6(2):159–67. Epub 2013/06/12. https://doi.org/10.1007/s12307-013-0139-3 PMID: 23749739; PubMed Central PMCID: PMC3717058.

44. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. International journal of
radiation oncology, biology, physics. 2013; 86(2):343–9. Epub 02/22. https://doi.org/10.1016/j.ijrob.2012.12.025 PMID: 23462419.

45. Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, et al. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 2017; 23(1):124–36. Epub 06/29. https://doi.org/10.1158/1078-0432.CCR-15-1535 PMID: 27358487.

46. Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM, et al. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2018; 24(11):2559–73. Epub 2018/03/04. https://doi.org/10.1158/1078-0432.ccr-17-3573 PMID: 29500275; PubMed Central PMCID: PMC5984675.

47. Karachi A, Dastmalchi F, Mitchell DA, Rahman M. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro-oncology. 2018; 20(12):1566–72. https://doi.org/10.1093/neuonc/noy072 PMID: 29733389